Status:
COMPLETED
Drip-infusion of Remifentanil for RIH
Lead Sponsor:
Tri-Service General Hospital
Conditions:
Hyperalgesia
Eligibility:
All Genders
20-80 years
Brief Summary
The development of remifentanil-induced hyperalgesia (RIH) is an unpleasant experience for surgical patients. An alternative management, gradual withdrawal of remifentanil was effective in prevention ...
Detailed Description
In clinical practice, the gradual withdrawal of remifentanil during surgery is unsatisfied. Thus, the investigators conducted a simple modality in a single center retrospective cohort study to assess ...
Eligibility Criteria
Inclusion
- American Society of Anesthesiologists (ASA) score of I-III patients receiving total intravenous anesthesia
Exclusion
- The use of inhalation agents or propofol combined with inhalation anesthesia
- Pregnancy
- Previous substance abuse
- Known allergies to opioids, propofol or any drugs used in the study
- History of neuropsychiatric disorder
- Age \< 20 years or \> 80 years
Key Trial Info
Start Date :
May 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 22 2019
Estimated Enrollment :
559 Patients enrolled
Trial Details
Trial ID
NCT04387097
Start Date
May 1 2018
End Date
July 22 2019
Last Update
May 15 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
TriService General Hospital
Taipei, Taiwan, 11490